Literature DB >> 11158767

Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.

R Patel1, M S Rouse, K E Piper, J M Steckelberg.   

Abstract

We compared the activities of linezolid (25 mg/kg of body weight, administered intraperitoneally every 8 h) and of vancomycin (25 mg/kg of body weight, administered intraperitoneally every 8 h) in a rat model of vanA vancomycin-resistant Enterococcus faecium experimental endocarditis. Results were expressed as median log(10) CFU per gram of vegetation after 3 days of treatment. The median log(10) CFU per gram of vegetation was 10.1 among 7 untreated control animals, 10.2 among 9 vancomycin-treated animals, and 7.9 among 10 linezolid-treated animals. Linezolid treatment was more active (P < 0.05) than vancomycin treatment or no treatment.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11158767      PMCID： PMC90339          DOI： 10.1128/AAC.45.2.621-623.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Multiplex PCR detection of vanA, vanB, vanC-1, and vanC-2/3 genes in enterococci.

Authors:  R Patel; J R Uhl; P Kohner; M K Hopkins; F R Cockerill
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

2.  Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Authors:  A Saleh-Mghir; A Lefort; Y Petegnief; S Dautrey; J M Vallois; D Le Guludec; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.

Authors:  S Matsumura; A E Simor
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

4.  In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

Authors:  R Patel; M S Rouse; K E Piper; F R Cockerill; J M Steckelberg
Journal:  Diagn Microbiol Infect Dis       Date:  1998-02       Impact factor: 2.803

5.  In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

Authors:  C W Ford; J C Hamel; D M Wilson; J K Moerman; D Stapert; R J Yancey; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.

Authors:  J W Chien; M L Kucia; R A Salata
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

7.  Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.

Authors:  T Schülin; C Thauvin-Eliopoulos; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

8.  The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.

Authors:  R C Moellering; P K Linden; J Reinhardt; E A Blumberg; F Bompart; G H Talbot
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

9.  Linezolid therapy of Staphylococcus aureus experimental osteomyelitis.

Authors:  R Patel; K E Piper; M S Rouse; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

10.  Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci.

Authors:  W C Hellinger; M S Rouse; P M Rabadan; N K Henry; J M Steckelberg; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191
View more
  8 in total

1.  Occurrence of MRSA endocarditis during linezolid treatment.

Authors:  E H Ben Mansour; E Jacob; M Monchi; D Ledoux; J-L Canivet; P De Mol; P Damas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-27       Impact factor: 3.267

2.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

3.  Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.

Authors:  George Athanassopoulos; Angelos Pefanis; Vissaria Sakka; Dimitrios Iliopoulos; Despina Perrea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study.

Authors:  T K Lauridsen; L E Bruun; R V Rasmussen; M Arpi; N Risum; C Moser; H K Johansen; H Bundgaard; C Hassager; N E Bruun
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-20       Impact factor: 3.267

5.  Fsr-independent production of protease(s) may explain the lack of attenuation of an Enterococcus faecalis fsr mutant versus a gelE-sprE mutant in induction of endocarditis.

Authors:  Kavindra V Singh; Sreedhar R Nallapareddy; Esteban C Nannini; Barbara E Murray
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Medical treatment of endocarditis.

Authors:  Elias Abrutyn; Christopher H Cabell; Vance G Fowler; Bruno Hoen; José M Miro; Carlos A Mestres; Daniel J Sexton; G Ralph Corey
Journal:  Curr Infect Dis Rep       Date:  2007-07       Impact factor: 3.725

7.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

8.  Linezolid for infective endocarditis: A structured approach based on a national database experience.

Authors:  P Muñoz; S De la Villa; M Martínez-Sellés; M A Goenaga; K Reviejo-Jaka; F Arnáiz de Las Revillas; L García-Cuello; C Hidalgo-Tenorio; M A Rodríguez-Esteban; I Antorrena; L Castelo-Corral; E García-Vázquez; J De la Torre; E Bouza
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.